In the BioHarmony Drug Report Database

"Preview" Icon

Nilutamide

Nilandron, Xtandi (nilutamide) is a small molecule pharmaceutical. Nilutamide was first approved as Nilandron on 1996-09-19. It is used to treat carcinoma and prostatic neoplasms in the USA. It has been approved in Europe to treat prostatic neoplasms. The pharmaceutical is active against androgen receptor.

 

Trade Name

 

Xtandi
 

Common Name

 

nilutamide
 

ChEMBL ID

 

CHEMBL1274
 

Indication

 

carcinoma, prostatic neoplasms
 

Drug Class

 

Non-steroid antiandrogens

Image (chem structure or protein)

Nilutamide structure rendering